Restless legs syndrome in fabry disease: clinical feature associated to neuropathic pain is overlooked;Síndrome de piernas inquietas en la enfermedad de Fabry: Asociación con dolor neuropático

Revista de Neurologia

Volumn 45, Issue 8, 2007, Pages 474-478

  Domínguez, Raúl O ^a   Michref, A ^a   Tanus, E ^a   Amartino, H ^b  

^a Asociacion de Beneficencia Hospital Sirio Libanes Buenos Aires   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

Author keywords

Crisis Fabry; Enzyme replacement therapy; Fabry disease; Neuropathic pain; Neuropathy of small fiber; Restless legs syndrome

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; NEUROPATHIC PAIN; RESTLESS LEGS SYNDROME; WALKING; MIDDLE AGED; NEURALGIA; PATHOPHYSIOLOGY;

ADULT; FABRY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; RESTLESS LEGS SYNDROME;

EID: 37349024698     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4508.2007417     Document Type: Article

References (26)

1. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995; 10: 634-42.
2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health, International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-19.
3. Nineb A, Rosso C, Dumurgier J, Nordine T, Lefaucheur JP, Créange A. Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. Eur J Neurol 2007; 14: 788-92.
4. Gemignani F, Brindani F, Vitetta F, Marbini A, Calzetti S. Restless legs syndrome in diabetic neuropathy: a frequent manifestation of small fiber neuropathy. J Peripher Nerv Syst 2007; 12: 50-3.
5. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science 1970; 167: 1268-9.
6. Vetrie D, Kendall E, Goffey A, Hassock S, Collins J, Todd C, et al. A 6.5 Mb yeast artificial chromosome contig incorporating 33 DNA markers on the human chromosome at Xq22. Genomics 1994; 19: 42-7.
7. Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic bases of inherited disease. 8 ed. New York: McGraw-Hill; 2001. p. 3733-74.
8. Politei JM, Pagano MA. Neuropatía periférica en la enfermedad de Anderson-Fabry: fisiopatología, evaluación y tratamiento. Rev Neurol 2004; 38: 979-83.
9. Barba-Romero MA, García de Lorenzo y Mateos A, Grupo Español de Estudio de FOS. Fabry's disease in Spain. Study of 24 cases. Med Clin (Barc) 2004; 123: 57-60.
10. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C, Ad and Ab nerve fibers in Fabry neuropathy. Neurology 2004; 62: 1066-72.
11. López M. Enfermedad de Fabry: una entidad multidisciplinar con nuevas perspectivas terapéuticas. Rev Clin Esp 2003; 203: 292-5.
12. Domínguez RO, Amartino H, Chamoles NA, Grupo de Estudio de la Enfermedad de Fabry. Dolor neuropático en la enfermedad de Fabry: remisión heterogénea en tres años de tratamiento de reemplazo enzimático. Rev Neurol 2006; 43: 201-6.
13. Mendióroz M, Fernández-Cadenas I, Montaner J. Manifestaciones neurológicas de la enfermedad de Fabry. Rev Neurol 2006; 43: 739-45.
14. Huskisson EC. Measurement of pain (VAS). Lancet 1974; 2: 1127-31.
15. Scott LJ, Griffing JW, Luciano C, Barton NW, Banerjee T, Crawford JC, et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999; 52: 1249-54.
16. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975; 12: 189-98.
17. Schwarb S, Koberle S, Spiegel R. The Alzheimer's Disease Assessment Scale (ADAS): an instrument for early diagnosis of dementia. Int J Geriatr Psychiatry 1988; 3: 45-53.
18. Shulman K, Shedletsky R, Silver I. The challenge of time: clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1986; 1: 135-40.
19. Hughes CP, Berg L, Danziger WL, Coban LA, Martin RL. A new clinical scale for the staging of dementia (CDR). Br J Psychiatry 1982; 140: 566-72.
20. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160: 2137-41.
21. Berger K, Von Eckardstein A, Trenkwalder C, Rothdach A, Junker R, Weiland SK. Iron metabolism and the risk of restless legs syndrome in an elderly general population -the MEMO study. J Neurol 2002; 249: 1195-9.
22. Pérez-Romero T, Comas-Fuentes A, Debán-Fernández M, González-Nuevo Quiñones JP, Maujo-Fernández J. Prevalencia del síndrome de piernas inquietas en las consultas de atención primaria. Rev Neurol 2007; 44: 647-51.
23. Kryger MH, Otake K, Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med 2002; 3: 127-32.
24. Manconi M, Fabbrini M, Bonanni E, Filippi M, Rocca M, Murri L, et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007; 14: 534-9.
25. Tunç T, Karada YS, Doulu F, Inan LE. Predisposing factors of restless legs syndrome in pregnancy. Mov Disord 2007; 22: 627-31.
26. Culebras A. Síndrome de las piernas inquietas. Diagnóstico y tratamiento. Rev Neurol 2001; 32: 281-3.